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Abstract
Self-extracellular RNA (eRNA), released from stressed or injured cells upon various patho-
logical situations such as ischemia-reperfusion-injury, has been shown to act as an alarmin
by inducing procoagulatory and proinflammatory responses. In particular, M1-polarization
of macrophages by eRNA resulted in the expression and release of a variety of cytokines,
including tumor necrosis factor (TNF)-α or interleukin-6 (IL-6). The present study now
investigates in which way self-eRNA may influence the response of macrophages towards
various Toll-like receptor (TLR)-agonists. Isolated agonists of TLR2 (Pam2CSK4), TLR3
(PolyIC), TLR4 (LPS), or TLR7 (R848) induced the release of TNF-α in a concentration-
dependent manner in murine macrophages, differentiated from bone marrow-derived stem
cells by mouse colony stimulating factor. Here, the presence of eRNA shifted the dose-
response curve for Pam2CSK4 (Pam) considerably to the left, indicating that eRNA syner-
gistically enhanced the cytokine liberation from macrophages even at very low Pam-levels.
The synergistic activation of TLR2 by eRNA/Pam was duplicated by other TLR2-agonists
such as FSL-1 or Pam3CSK4. In contrast, for TLR4-agonists such as LPS a synergistic
effect of eRNA was much weaker, and was not existent for TLR3-, or TLR7-agonists. The
synergistic eRNA/Pam action was dependent on the NFκB-signaling pathway as well as
on p38MAP- and MEK1/ERK-kinases and was prevented by predigestion of eRNA with
RNase1 or by antibodies against TLR2. Thus, the presence of self-eRNA as alarming mole-
cule sensitizes innate immune responses towards pathogen-associated molecular patterns
(PAMPs) in a synergistic way and may thereby contribute to the differentiated outcome of
inflammatory responses.
PLOS ONE | https://doi.org/10.1371/journal.pone.0190002 December 20, 2017 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Noll F, Behnke J, Leiting S, Troidl K, Alves
GT, Mu¨ller-Redetzky H, et al. (2017) Self-
extracellular RNA acts in synergy with exogenous
danger signals to promote inflammation. PLoS
ONE 12(12): e0190002. https://doi.org/10.1371/
journal.pone.0190002
Editor: David M. Ojcius, University of the Pacific,
UNITED STATES
Received: September 4, 2017
Accepted: December 6, 2017
Published: December 20, 2017
Copyright: © 2017 Noll et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: Studies were generously supported by
grants to K.T. Preissner, S. Fischer, and H. Mu¨ller-
Redetzky from the German Research Foundation
(DFG, Bonn, Germany, http://www.dfg.de),
including SFB TR84 (SF and HM-R), FI 543/4-1
(SF), the Excellence Cluster-Cardiopulmonary
System (KTP, ECCPS, Giessen, Germany, http://
eccps.de), by the Behring-Ro¨ntgen Foundation (SF,
Introduction
The innate immune system protects against infectious microbes by the recognition of PAMPs,
which serve to detect pathogens on the host cell surface or in endosomes by pattern recogni-
tion receptors (PRRs) like Toll-like receptors (TLRs), Nucleotide-binding oligomerization
domain-containing protein-1 (NOD1)-like receptors, mannose receptor, or retinoic acid-
inducible gene-1-like receptors that initiate proper host defense mechanisms [1,2]. In addition
to PAMPs, a series of endogenous danger-associated molecular patterns (DAMPs) are recog-
nized by PRRs, thereby serving as body´s own alarm signals under conditions of stress or
injury [3–5]. Among such DAMPs are heat shock proteins, high mobility group box 1 protein
(HMGB-1), aged matrix proteins, S100 proteins, as well as nucleic acids. These usually intra-
cellular factors acquire extracellular functions when released from cells by either passive or
active processes [6]. Thus, DAMPs function as „alarmins”to alert the body about danger or
disease by triggering inflammation, dendritic cell maturation, and stimulate the immune
response resulting in the release of cytokines, which in turn can augment the local inflamma-
tory environment [7]. Many DAMPs (like PAMPs) are recognized by PRRs in a promiscuous
fashion by TLR2, TLR4, or the receptor for advanced glycation end products (RAGE) [3,8].
Binding of DAMPS or PAMPs to TLRs activates either myeloid differentiation factor 88
(MyD88)—dependent or Toll/interleukin-1 receptor domain containing adaptor inducing
interferon β (TRIF)—dependent signaling pathways, resulting in the activation of transcrip-
tion factors like JNK or NF-κB, followed by the release of cytokines including TNF-α, interleu-
kins (IL)-1β, or IL-6 [9,10].
Self eRNA released under pathological conditions such as myocardial ischemia-reperfusion
injury has been described to activate the TLR3-Trif pathway and to induce inflammatory
responses in cardiomyocytes and immune cells by TLR7-signaling, which were both abolished
by pretreatment of RNA samples with RNase, but not DNase [11,12]. Furthermore, RAGE
was identified to bind eRNA and to enhance its cellular uptake into endosomes leading to an
enhanced TLR response [13]. Accordingly, in previous studies we have characterized self-
extracellular RNA (eRNA) as a new alarmin, which induces prothrombotic, permeability-
increasing, and inflammation-promoting responses in immune and vascular cells [14–19]. In
these investigations, eRNA was used as single agonist at rather high concentrations and for
extended incubation periods with different in vitro cell culture systems [14,17]. In the present
study, the inflammatory potential of eRNA in the presence of additional PAMPs and DAMPS
was tested, whereby eRNA was found to serve as potent adjuvant, particularly for TLR2 ligands
to enhance their proinflammatory potential in a synergistic manner. Thus, the presence of
self-DAMPs such as eRNA during situations of microbial infection may very well potentiate
the outcome of inflammation, and counteracting regimen such as administration of RNase1
could be of potential therapeutic value.
Materials and methods
Cell culture
Primary bone marrow derived macrophages (BMDM) were obtained from bone marrow cells
(BMCs), which were flushed from the bones of C57Bl/6 mice. Animal care and all experimen-
tal procedures were performed in strict accordance to the German and National Institutes of
Health Animal Legislation Guidelines and were approved by the local animal care and use
committees (Regierungspra¨sidium Giessen). BMCs were cultured in DMEM medium (Gibco)
containing 10% fetal calf serum (FCS, Gibco) and differentiated by mouse-colony stimulating
factor, which is secreted by L929 cells and is used in the form of L929-conditioned medium.
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Under these conditions, BMDM proliferate and differentiate into a homogenous population
of mature BMDMs after 1 week. The efficiency of the differentiation was assessed by fluores-
cence-activated cell sorting (FACS) analysis of antigens F4/80, CD68 and CD11b, reaching a
cellular purity of about 90%. To stimulate BMDM in future experiments, 2 x 106 cells/ml
RPMI were used.
The following agents at the indicated concentrations were used for cell stimulations: lipo-
polysaccharide (LPS) from Sigma-Aldrich (Mu¨nchen, Germany), Pam2CSK4, Pam3CSK4,
FSL-1, polyIC, R848, and MAb-mTLR2 from InvivoGen (Toulouse, France), PD98059 and
SB203580 from Calbiochem (Merk, Darmstadt, Germany), Bay 11–7082 from Enzo Life Sci-
ences (Lo¨rrach, Germany), and TNF-α receptor antagonist WP9QY from Santa Cruz (Heidel-
berg, Germany). Prior to stimulation, cells were washed once with phosphate-buffered saline
(PBS) and incubated for the indicated time periods in cell culture medium containing the dif-
ferent agents at the indicated concentrations. Stimulation of cells with Pam2CSK4/eRNA mix-
tures was performed after preincubating both agents in PBS for 1 h at 37˚C.
Isolation and quantification of RNA and DNA
Total cellular RNA and DNA were isolated from macrophages or from confluent cultures of
fibroblasts using an extraction kit (Peqlab, Erlangen, Germany) or the DNAzol reagent (Invi-
trogen, Groningen, The Netherlands). eRNA, which was used to stimulate cells, was purified
from confluent cultures of fibroblasts by using the TRIzol™ reagent, followed by precipitation
with isopropanol and resuspending the RNA in RNase-free water. Subsequently, the dissolved
RNA was additionally purified using the TRIzol LS reagent in accordance with instructions of
the manufacturer (Thermo Fisher Scientific, Darmstadt, Germany). To isolate eRNA from cell
supernatants, fibroblasts or epithelial cells were stimulated with small, non-toxic concentra-
tions of the pore-forming bacterial toxin pneumolysin (200 ng/ml; friendly supplied by Profes-
sor Tim Mitchell, Birmingham, USA) for 1 h. Cell-supernatants were first centrifuged for 5
min at 200 x g to remove cells and cell debris. To prevent degradation of RNA, RNase inhibitor
(4 U/ml, RNasin, Invitrogen) was added and samples were concentrated using centricon tubes
(cut off 10 kD; Millipore) that were centrifuged at 3400 x g for 12 min at 4˚C and subsequently
washed with autoclaved sterile water. Same amounts of lysis buffer (peqGOLD total RNA kit
from Peqlab) were added to the concentrated cell supernatants and RNA was isolated in accor-
dance with the instructions of the manufacturer. Total RNA and DNA were quantified using a
NanoDrop 2000 (Thermo Fisher Scientific). Quality of RNA and DNA was confirmed by elec-
trophoresis on 1% agarose gels followed by ethidium bromide staining or by using the Agilent
2100 bioanalyzer and the Agilent RNA 6000 Nano Kit (Agilent Technologies, Konstanz, Ger-
many). The quality of RNA isolated from cell supernatants or lysates was identical, but the
amount of RNA isolated from cell supernatants was rather small (4–7 μg from 6 x 106 cells)
compared to cell lysates. Purity of RNA was confirmed by performing the endotoxin test using
the PierceTM LAL chromogenic endotoxin quantification kit (Thermo Fisher Scientific). The
concentration of endotoxin found in RNA preparations used for the stimulation of cells was
always < 0.1 endotoxin Units (EU)/ml, which correlates to 0.01 ng/ml of endotoxin. These
concentrations of endotoxin did not induce any inflammatory response.
Binding of biotinylated RNA to proteins
Wells of a microtiter plates were coated each with 50 μl solution of platelet factor 4 (PF4),
TLR2, CD14, CD36 (each from PeproTech, London, UK), or bovine serum albumin (BSA)
(10 μg/ml each) in 100 mM sodium carbonate (pH 9.5) at 4˚C for 20 h. Wells were washed and
blocked for 2h with Tris-buffered saline (TBS) containing 3% BSA. Different concentrations of
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biotinylated RNA (0. 78–50 μg/ml), prepared from RNA using the Psoralen-PEO-Biotin
reagent (Pierce, Rockford, IL), were allowed to bind at 22˚C for 2 h followed by 3 times wash-
ing with TBS. Bound biotinylated RNA was detected using peroxidase-conjugated streptavidin
(Dako, Glostrup, Denmark) and the immunopure TMB (3,3’,5,5’-tetramethylbenzidine) sub-
strate kit (Pierce) by measuring the reaction products at 450 nm. Binding of biotinylated RNA
to PF4 and BSA was considered as positive and negative controls, respectively [20].
Quantitative real-time PCR (qPCR)
Following treatment of BMDM with various agonists as indicated in the legends of the corre-
sponding figures, cells were washed twice with PBS, lysed, and RNA was isolated with the total
RNA extraction kit (Peqlab). For qPCR analysis, 1 μg of RNA was reverse-transcribed using
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA)
and DNA amplification was performed with a StepOne Plus cycler (Applied Biosystems) in a
reaction volume of 10 μl using the SensiMix Sybr Kit (Bioline, Luckenwalde, Germany) with
50 pmol of each primer. To avoid amplification of genomic DNA, primers were designed to
span exon-exon junctions. The qPCR was performed under the following conditions: an initial
denaturation step at 95˚C for 8.5 min followed by 45 cycles, consisting of denaturation (95˚C,
30 s), annealing (60˚C, 30 s) and elongation (72˚C, 30 s). Melt curve analysis was performed to
control specific amplification. Results were normalized to the expression levels (E) of actin and
expressed as the ratio of E(target)/E(Actin). The following mouse primers were used: TNF-α
forward ACTGAACTTCGGGGTGATCG, TNF-α reverse TGGTTTGTGAGTGTGAGGGTC, IL-6
forward CTCTGCAAGAGACTTCCATCCA, IL-6 reverse TTGTGAAGTAGGGAAGGCCG, actin
forward CGCGAGCACAGCTTCTTTG, actin reverse CGTCATCCATGGCGAACTGG, IL-1β for-
ward GGATGAGGACATGAGCACCT, IL-1β reverse GGAGCCTGTAGTGCAGTTGT,MCP-1 for-
ward AAGCTGTAGTTTTTGTCACCAAGC, MCP-1 reverse GACCTTAGGGCAGATGCAGTT.
TNF-α- and IL-6-ELISA
Macrophages were treated for different time periods with various agents as indicated in the
corresponding figure legends. TNF-α- and IL-6- ELISA was performed using the commer-
cially available kit from eBioscience (Frankfurt, Germany).
Statistical analysis
Each experiment was repeated at least three times. The mean values are presented as
mean ± standard error of the mean (SEM). The data of each figure were analysed using one
way analysis of variance (ANOVA) followed by multiple comparisons between different
groups by the Bonferroni Multiple Comparison Test. All statistical analyses were performed
using GraphPad Prism (version 5.0). A value p< 0.05 was considered to represent statistical
significance.
Results
Synergistic function of eRNA and PAMPs on the activation of TLR-2
To investigate the influence of eRNA on the PAMP-mediated release of TNF-α from macro-
phages, cells were treated with different concentrations of the TLR-2/6 agonist Pam2CSK4
(Pam) in the absence or presence of eRNA. Pam alone at concentrations 0.3 ng/ml increased
the TNF-α release in a concentration-dependent manner after two hours of stimulation. How-
ever, in the presence of eRNA, a significant shift of the dose-response curve to the left was
observed, resulting in a dramatic increase of TNF-α release already at more than tenfold lower
Synergism of extracellular RNA with exogenous danger signals to promote inflammation
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Pam concentrations (0.01–0.03 ng/ml). Only at Pam-concentrations 1 ng/ml, the difference
between the TNF-α release induced by Pam alone or in combination with eRNA was no more
significant (Fig 1A). Accordingly, the mRNA expression of inflammatory cytokines, such as
TNF-α, IL-6, IL-1β and monocyte chemoattractant protein-1 (MCP-1) were significantly ele-
vated by Pam concentrations 0.03 ng/ml in the presence of eRNA (Fig 1C–1F). Not only
eRNA, consisting mostly of ribosomal RNA, but also tRNA promoted the release of TNF-α up
to 70-fold in the presence of suboptimal concentrations of Pam (0.1 ng/ml), which had no
stimulatory function on its own. eDNA exhibited moderate synergistic activity together with
Pam (Fig 1B). The synergistic activation of TLR2 by eRNA/Pam was only expressed if both
agonists were preincubated for at least 1h prior to cell stimulation. Predigestion of eRNA with
RNase1 reduced the release of TNF-α at the Pam concentration of 0.1 ng/ml to 39 ± 11% com-
pared to the cytokine release induced by eRNA/Pam mixture, confirming the involvement of
eRNA in the synergistic activation of TLR2. However, activity of eRNA was independent of its
binding to TLR2 or to cofactors of TLRs such as CD36 and CD14 as was demonstrated by a
binding assay of biotinylated RNA to each of these proteins (S1 Fig).
The dose-response curve of eRNA in the presence of low, by itself inactive Pam concentra-
tion (0.1 ng/ml), revealed that the presence of increasing eRNA concentrations resulted in a
significant concomitant increase in the release of TNF-α. In particular, the ratio of TNF-α
release determined in the presence versus the absence of Pam increased from 30-fold at 0.1 ng/
ml eRNA to maximal 200-fold at 10 μg/ml eRNA (Fig 2A). Accordingly, the mRNA expression
of TNF-α, IL-6, IL-1β and MCP-1 reflected the same profile of the dose-response curve of
eRNA in the presence of 0.1 ng/ml Pam (Fig 2B–2E).
Similar results were obtained when the TLR2/6 agonist FSL-1 instead of Pam was used: At
concentrations 0.03 ng/ml– 0.3 ng/ml of FSL-1, eRNA significantly increased the release of
TNF-α protein from macrophages compared to the cytokine release induced by FSL-1 alone,
whereas the differences in the induction of TNF-α mRNA expression became only obvious at
a FSL-1 concentration of 0.1 ng/ml (Fig 3A and 3C). By using the TLR2/1 agonist Pam3CSK4,
the sensitizing effects of eRNA on TLR2 activation became significant only at higher concen-
trations of Pam3CSK4 (> 1 ng/ml) compared to the previously mentioned TLR2/6 agonists,
whereas TNF-α mRNA expression was not changed in the presence of eRNA (Fig 3B and 3D).
The mRNA expression of IL-6, IL-1β and MCP-1 exhibited the same profile of the dose-
response curve of FSL-1 and Pam3CSK4 in the presence of eRNA (10 μg/ml) as was observed
for mRNA expression and release of TNF-α (S2 Fig).
Time-dependent TLR2 activation by combined agonists
The sensitizing effect of eRNA on the Pam-mediated TNF-α release could be further increased
by prolonged exposure of macrophages towards these agonists. For example, upon exposure of
cells towards eRNA/Pam for longer time periods, the mRNA expression of TNF-α IL-6, IL-1β
and MCP-1 increased up to 6 h, but thereafter, it decreased or totally declined, respectively
(Fig 4C–4F). Using the same experimental setting, the release of TNF-α protein increased up
to 6 h and then remained unchanged, whereas the release of IL-6 protein only started after 6 h
of treatment (Fig 4A and 4B).
To exclude that autocrine effects of TNF-α were involved in the activation of macrophages,
cell stimulation was performed in the presence of a TNF-α-receptor antagonist. The TNF-α
release induced by eRNA/Pam in the presence of the TNF-α-receptor blocker was unchanged
after 2 h of treatment, whereas after 6 h, the cytokine release was significantly reduced by the
TNF-α-receptor antagonist (S3 Fig). Thus, activation of macrophages was performed only for
2 h to prevent any interfering effects by TNF-α itself.
Synergism of extracellular RNA with exogenous danger signals to promote inflammation
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Fig 1. Sensitizing function of eRNA on TLR2 activation by Pam2CSK4. Macrophages were treated for 2 h with
different concentrations of Pam2CSK4 in the presence of eRNA (10 μg/ml) or buffer (A, C-F) or a fixed concentration
of Pam2CSK4 (0.1 ng/ml) or buffer in the presence of eRNA, tRNA, or eDNA (each 10 μg/ml) (B). Prior to cell
stimulation, nucleic acids and Pam2CSK4 were preincubated for 1 h at 37˚C. Cell supernatants were analyzed for the
release of TNF-α by ELISA. The mRNA expression of TNF-α (C), IL-6 (D), IL1β (E), and MCP-1 (F) was assessed
from macrophage lysates by qRT-PCR. Values are expressed as mean ± SEM; N = 3–12; *P < 0.05 between groups.
https://doi.org/10.1371/journal.pone.0190002.g001
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Fig 2. Sensitizing function of different concentrations of eRNA on TLR2 activation. Macrophages were
treated for 2 h with different concentrations of eRNA in the presence of Pam2CSK4 (0.1 ng/ml) or buffer. Prior to
cell stimulation, eRNA and Pam2CSK4 were preincubated for 1 h at 37˚C. Supernatants of cells were analyzed for
the release of TNF-α by ELISA (A). mRNA expression of TNF-α (B), IL-6 (C), IL1β (D), and MCP-1 (E), was
assessed from cell lysates by qRT-PCR. Values are expressed as mean ± SEM; N = 3; *P < 0.05 between groups.
https://doi.org/10.1371/journal.pone.0190002.g002
Synergism of extracellular RNA with exogenous danger signals to promote inflammation
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Signaling pathways involved in TLR2 activation by combined eRNA/Pam
treatment
To confirm the involvement of TLR2 in the macrophage response towards the combined
agonists eRNA/Pam, a TLR2 neutralizing antibody was shown to abrogate not only the
Fig 3. Sensitizing function of eRNA on TLR2 activation by TLR2-agonists FSL-1 and Pam3CSK4. Macrophages were treated for 2 h with
different concentrations of FSL-1 (A,C) or Pam3CSK4 (B,D) in the presence of eRNA (10 μg/ml) or buffer. Prior to cell stimulation, eRNA was
preincubated with FSL-1 or Pam3CSK4 for 1 h at 37˚C. Supernatants of cells were analyzed for the release of TNF-α by ELISA (A,B) and mRNA
expression of TNF-αwas determined from cell lysates by qRT-PCR (C,D). Values are expressed as mean ± SEM; N = 3–8; *P < 0.05 between groups.
https://doi.org/10.1371/journal.pone.0190002.g003
Synergism of extracellular RNA with exogenous danger signals to promote inflammation
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Fig 4. Time-dependent cytokine expression from macrophages treated with eRNA/Pam2CSK4.
Following preincubation of eRNA (10 μg/ml) and Pam2CSK4 (0.1 ng/ml) for 1 h at 37˚C, macrophages were
treated with these combined agonists (eRNA+Pam2CSK4), eRNA, Pam, or buffer for different time periods as
indicated. Supernatants of cells were analyzed for the release of TNF-α (A) and IL-6 (B) by ELISA. mRNA
expression of TNF-α (C), IL-6 (D), IL-1β (E), and MCP-1 (F) was assessed from cell lysates by qRT-PCR.
Values are expressed as mean ± SEM; N = 3; *P < 0.05 versus buffer-treated group.
https://doi.org/10.1371/journal.pone.0190002.g004
Synergism of extracellular RNA with exogenous danger signals to promote inflammation
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eRNA/Pam-induced increase in TNF-α protein but also the mRNA expression of TNF-α, IL-
6, IL-1β, and MCP-1 (Fig 5A–5E). Moreover, the release of active TNF-α protein, which
depends on the activation of the sheddase ADAM17, was abolished by the ADAM17-inhibitor
TAPI (Fig 5A). Since the activation of TLR2 involves engagement of the NFκB-pathway in any
case, mRNA expression and protein release were totally blocked by the NFκB pathway inhibi-
tor Bay. In contrast, blockade of MAPkinases 42/44 and 38 by PD98059 and SB203580, respec-
tively, partially reduced the release of TNF-α protein but did not affect mRNA expression of
this cytokine (Fig 5A and 5B) and had variable effects on mRNA expression of IL-6, IL-1β, and
MCP-1 (Fig 5C–5E). No change in the cytokine mRNA expression or protein release was
observed if these inhibitors were used in the absence of TLR2 agonists. While the expression of
TLR2 itself was slightly increased by eRNA or Pam alone and eRNA/Pam as well, other TLRs
such as TLR3, 4 or 7 were not significantly affected in their mRNA expression upon exposure
to either one of these agonists (S1 Supplement).
Influence of eRNA on the activation of TLR 3, 4, and 7
eRNA only slightly induced the activation of TLR4 by LPS, since at 1 ng/ml LPS (but not
below or above this concentration) the release of TNF-α was moderately but significantly
increased by eRNA (Fig 6A) without any remarkable effect on mRNA expression (Fig 6D). In
contrast, eRNA had no influence on the activation of TLR7 and TLR3 by R848 and polyIC, as
measured by the release of TNF-α (Fig 6B, 6C, 6E and 6F).
Discussion
In the present study, self-eRNA was identified as a synergistic cofactor for Pam2CSK4, a typi-
cal TLR2 agonist, to strongly enhance macrophage activation. The combined action of eRNA
and Pam was not apparent for endosomal TLRs such as TLR3, TLR 7, or TLR 8, which all rec-
ognize non-self RNA. However, under conditions of high abundance of self RNAs resulting
from cell damage, defects in the RNA-degradation machinery, or after bindung and cellular
uptake of RNA into endosomes, such self RNAs may activate endosomal PRRs [13,21]. The
combined action of eRNA/Pam resulted in a substantially elevated mRNA expression and
release of cytokines in murine bone marrow-derived macrophages, whereas each single agonist
at the same concentration was ineffective. Thus, the synergistic action of eRNA and Pam
demonstrates a novel example of pathogen recognition and sensitization by host cells that is
markedly influenced by DAMPs/alarmins and may only be observed in situations where a cer-
tain degree of cell stress or trauma with the release of eRNA has occured.
Another well-studied example of synergistic pathogen sensitization is CD14, the co-recep-
tor for TLR4 in the recognition of LPS and the internalization of TLR2 ligands such as lipotei-
choic acid or Pam3CSK4 [22–24]. Moreover, CD14 also binds to triacylated lipopeptides
facilitating their recognition by TLR2/TLR1 complexes [22]. Another case is CD36, which
mainly acts as a sensor of diacylated lipopeptides that become recognised by TLR2/TLR6 [25].
The large difference between these surface-associated host proteins and eRNA is that the latter
becomes released as DAMP upon cell stress or damage anywhere in the organism and thereby
may fulfill a universal role as alarmin and sensitizer of TLR2-dependent cell responses.
As eRNA does not directly bind to CD14 or CD36 and also not to TLR2 itself, it is fair to
assume that polymeric eRNA may serve as a scaffolding factor and could directly interact with
multiple basic Pam molecules to ensure their enhanced recognition by TLR2. This would
explain that Pam promotes cell activation at very low concentrations only in the presence of
eRNA. An equivalent type of mechanism was observed in an experimental system with eRNA
and vascular endothelial growth factor (VEGF) as interaction partners, since only in the
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Fig 5. Intracellular signaling involved in the synergistic eRNA/Pam2CSK4-mediated TLR2 activation.
Macrophages were pretreated with buffer, neutralizing antibodies against TLR2 (1 μg/ml), TAPI (10 μg/ml), Bay
(100 μM), PD98059 (20 μM), or SB203580 (10 μM) for 30 min, and stimulated for 2 h with eRNA (10 μg/ml)/
Pam2CSK4 (Pam, 0.1 ng/ml), which were preincubated for 1 h at 37˚C. Supernatants were analyzed for the release
of TNF-α by ELISA (A). Cell lysates were used for the quantification of mRNA expression of TNF-α (B), IL-6 (C), IL-1β
(D), and MCP-1 (E) by qRT-PCR. TNF-α release and mRNA expression induced by eRNA/Pam in the absence of
Synergism of extracellular RNA with exogenous danger signals to promote inflammation
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presence of eRNA very low doses of VEGF could operate to induce endothelial cell signaling
[16]. In the present study it became obvious that the synergistic action of eRNA on TLR2 acti-
vation was dependent on the respective TLR2 ligand, whereby Pam2CSK4 showed a much
higher synergistic response in comparison to FSL-1, although both ligands are known to
bind to TLR2/TLR6 heterodimers. Accordingly, synergistic activities of eRNA might rely on
additives were set to 100%. Values are expressed as mean ± SEM; N = 3; *P < 0.05 versus values from eRNA/Pam-
treated cells in the absence of additives.
https://doi.org/10.1371/journal.pone.0190002.g005
Fig 6. Influence of eRNA on the activation of TLRs. Macrophages were treated for 2 h with different concentrations of LPS (A), R848 (B), or poly IC
(C) in the presence of eRNA (10 μg/ml) or buffer. Prior to cell stimulation, eRNA was preincubated with each agonist for 1 h at 37˚C and supernatants of
cells were analyzed for the release of TNF-α by ELISA (A). mRNA expression of TNF-α (B), IL-6 (C), IL-1β (D), and MCP-1(E) was assessed from cell
lysates by qRT-PCR. Values are expressed as mean ± SEM. N = 3; *P < 0.05 between groups.
https://doi.org/10.1371/journal.pone.0190002.g006
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structure- and charge-dependent interactions with TLR2 ligands to facilitate TLR-activation.
Moreover, eRNA required preincubation with Pam2CSK4 prior to exposure towards macro-
phages to promote a synergistic TLR2-dependent response and eRNA digestion with RNase1
prior to the addition of Pam completely abolished eRNA/Pam-induced cytokine release.
Non-self bacterial DNA or RNA are protected from degradation, for example by their cap-
sids, until they are released within the endo-lysosomal compartment of host cells, whereas self
extracellular nucleic acids are degraded by nucleases, unless they are protected in nucleopro-
tein complexes or by association with cell membranes [26]. Nevertheless, self nucleic acids
may only reach endo-lysosomes and PRRs if bound to proteins or manipulated by e.g. trans-
fection agents. For example, the antimicrobial peptide LL37 or HMGB1 can bind and protect
RNA from degradation and shuttle it into endo-lysosomal compartments [27,28], while self-
RNA can be experimentally modified by transfection agents such as lipofectamin to reach
intracellular compartments [11,12]. The latter, however, does not reflect the natural situation
that was experimentally challenged in the present study. Since the degradation of eRNA by
RNase1 was not changed in the presence of Pam, the synergistic action of eRNA and Pam on
TLR2 activation appears not to be related to eRNA protection against RNase1. The cellular
activity of eRNA might also depend on heterodimerization of TLRs and the type of TLR
involved, as synergistic functions of eRNA were much stronger on agonists recognizing the
TLR2/TLR6- compared to the TLR2/TLR1-heterodimer. Moreover, only a minor eRNA-
dependent synergistic effect was seen for LPS in the activation of the TLR4 axis, and no influ-
ence was recognized for the typical RNA-receptors TLR3, TLR7 or TLR8. At high concentra-
tions of TLR3 agonist, poly IC, eRNA even seems to decrease the poly IC-induced TNF-α
expression slightly, but not significantly. Ligands of TLR3, like negatively charged double-
stranded RNA, are quite different from ligands of TLR2 such as Pam containing more basic
amino acids, which might change the binding modes of these ligands to their receptors in the
presence of eRNA. However, these results indicate that activities of DAMPs, which were iden-
tified to amplify the inflammatory response of PAMPs, differ appreciably regarding the activa-
tion of particular PRRs [29,30].
During longer periods of treatment, the continuous TNF-α release from macrophages was
apparently due to autocrine stimulation as well, since blockade of the macrophage TNF-α
receptor signaling resulted in diminished TNF-α-release. Activation of the inflammasome
leading to the caspase-1-dependent secretion of IL-1β seems not to be involved in the synergis-
tic action of eRNA/Pam on TLR2 activation, as no release of IL-1β was detectable even after
treatment of macrophages for longer time intervals up to 24 h [31].
Accordingly, a former study demonstrated DAMP-sensing of PRRs, whereby activation of
endosomal TLRs by self-eRNA resulted in the uptake of eRNA into endosomes in a sequence-
independent manner by binding to the receptor for advanced glycation end-products (RAGE),
which had been identified as a surface-expressed self-eRNA receptor [32]. Moreover, the
DAMP HMGB1 has been recognized as binding partner and general sentinel for immuno-
genic nucleic acids, as the absense of HMGB1 severely impaired the activation of TLR3, TLR7,
and TLR9 by their cognate nucleic acid ligands [28]. HMGB1 further plays an important role
in sepsis by facilitating the transfer of LPS to CD14 to initiate a TLR4-dependent proinflamma-
tory response [29]. Likewise, the extracellular matrix component biglycan can act as an endog-
enous ligand of TLR4 and TLR2 and thereby sensitizes cells towards LPS [33]. In accordance
with these general mechanisms, we now describe eRNA as a sentinel for the activation of TLR2
by its cognate PAMP agonists to amplify the release of cytokines.
As cytokine-inducing activity of eRNA/Pam was inhibited by neutralizing antibodies
against TLR2, Myd88-induced pathways are likely to be involved. Further signaling pathways
required for the eRNA/Pam2SCK4-induced cytokine release involved the transcriptional
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activation of the NF-κB system, because blockade of this pathway fully abrogated the mRNA-
expression as well as the release of TNF-α protein in macrophages. In contrast, MAPkinase
inhibitors only blocked the TNF-α release but not the mRNA expression, indicating the
involvement of these MAPkinases in the activation of ADAM17, which is necessary for the
shedding reaction of membrane-bound pro-TNF-α to release active soluble TNF-α [34]. As
TNF-α is liberated by the activation of ADAM17, this cytokine was already detected after 2 h
treatment with eRNA/Pam (both ineffective when used alone), whereas the release of IL-6 pro-
tein was detectable only after 6 h stimulation. Accordingly, the shedding of active TNF-α pro-
tein but not the mRNA expression of TNF-α, induced by eRNA/Pam, was blocked by TAPI,
an inhibitor of ADAM17. Surprisingly, the presence of TAPI significantly increased the
mRNA expression of IL-1β and MCP-1 indicating a self-regulatory mechanism to compensate
the missing TNF-α release.
Several studies demonstrated TLR activation even by isolated endogenous DAMPs, whereas
the corresponding signaling pathways remain largely unknown. The leucine-rich repeat motif
of TLRs has been shown to be involved in the binding of PAMPs, but there is evidence that
DAMPs require further cofactors or coreceptors for the optimal activation of TLRs and their
association with diverse signaling routes [33–37]. A recent study even indicates that the
reported cytokine expression in response to putative endogenous ligands may in fact be due to
PAMP contaminations [38,39].
In summary, in situations of cellular stress or upon infection, the DAMP eRNA serves a
prominent cofactor role in facilitating PAMP-mediated activation of TLR2. Only in a com-
bined fashion, eRNA and TLR2-agonists promote activation of TLR2 on macrophages, result-
ing in appreciable cytokine mRNA expression and release, whereas each single agonist at the
given concentration did not induce any inflammatory response. Thus, it is proposed that the
degree of tissue damage with the appearance of eRNA provides the appropriate condition for
PAMP-dependent TLR2 activation. As a consequence, chronic inflammatory diseases like
rheumatoid arthritis, cancer, or atherosclerosis may depend on such perpetuated proinflam-
matory responses uncovered in this study. In fact, eRNA was shown to be responsible for the
development of such diseases in preclinical experimental animal models, whereby RNase1
administration resulted in a significant blockade of the inflammatory outcome and in consid-
erable tissue protection [40–42].
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S1 Fig. Synergistic activities of eRNA/Pam2CSK4 on TLR2 activation: Time-dependent
preincubation. (A) Macrophages were treated with buffer (Control), Pam2CSK4 (Pam, 0.1
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release of TNF-α. Values are expressed as mean ± SEM. N = 3; P< 0.05 between groups. (C)
Binding of biotinylated RNA to immobilized PF4, TLR2, CD36, and CD14 was performed in a
solid binding assay and data are corrected for unspecific binding to BSA. Data represent the
mean ± SEM; N = 3.
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S2 Fig. Sensitizing function of eRNA on TLR2 activation by TLR2-agonists FSL-1 and
Pam3CSK4. Macrophages were treated for 2 h with different concentrations of FSL-1 (A-C)
or Pam3CSK4 (D-F) in the presence of eRNA (10 μg/ml) or buffer. Prior to cell stimulation,
eRNA and FSL-1 or Pam2CSK4 were preincubated for 1 h at 37˚C. mRNA expression of
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mean ± SEM; N = 3–8; P< 0.05 between groups.
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S3 Fig. Time dependent TNF-α release from macrophages treated with eRNA/Pam2CSK4.
Macrophages were treated with eRNA (10 μg/ml)/Pam2CSK4 (0.1 ng/ml) (preincubated for 1
h at 37˚C) for 2 h and 6 h in the presence of TNF-α receptor antagonist or buffer. Supernatants
were analyzed for the release of TNF-α. Values determined in the absence of TNF-α receptor
antagonist were set to 100%. Values are expressed as mean ± SEM; N = 3; P< 0.05 between
groups.
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S4 Fig. Influence of eRNA and Pam2CSK4 on the expression of Toll-like receptors. Macro-
phages were treated with eRNA (10 μg/ml), Pam2CSK4 (0.1 ng/ml), buffer, or the preincu-
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